

## PRELIMINARY AMENDMENT

### **AMENDMENTS TO THE SPECIFICATION**

**Amend the specification by adding before the first line the sentence:**

Page 8, delete the first full paragraph and insert the following paragraph:

As the antiplatelet agent of the present invention, 1) an arachidonic acid metabolism inhibitor (e.g., aspirin, ozgrel, ethyl icosapentate, dilazep); 2) an ADP receptor inhibitor (e.g., ticlopidine, clopidogrel, prasugrel); 3) a ~~glycoprotein-IIb/IIIa~~ glycoprotein-IIb/IIIa antagonist (e.g., abciximab, eptifibatide, tirofiban, lamifiban); 4) a phosphodiesterase inhibitor (e.g., cilostazol, dipyridamole and the like); 5) an adenylycyclase activator (e.g., beraprost sodium, ticlopidine, limaprost, beraprost); 6) a serotonin 5-HT<sub>2</sub> antagonist (e.g., sarpogrelate); 7) a thromboxan A<sub>2</sub> receptor antagonist (e.g., S-18204) and the like can be illustrated, particularly, aspirin, ticlopidine, cilostazol and clopidogrel are preferable.